Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 8833 - 8840 of 12085 results

The Future of Hoverboards: Federal Safety Standard or Voluntary Safety Standard?
December 17, 2015| Blog| Viewpoint

When a Quirk of Copyright Law Creates a Christmas Classic: It’s a Wonderful Life and the Public Domain
December 17, 2015| Blog| Viewpoint

Smartphone Wars – The Supreme Court Awakens: Samsung Files Petition for Certiorari in New Hope to Harmonize Design Patent Law
December 17, 2015| Blog| Viewpoint

Antitrust Suit Continues to Stymie New Texas Telemedicine Regulation
December 17, 2015| Blog| Viewpoint

Key EU Parliamentary Committee Votes to Adopt the General Data Protection Regulation
December 17, 2015| Blog| Viewpoint

Bigbelly Named One of Boston’s “50 on Fire”
December 16, 2015| Blog| Viewpoint

FTC Alleges “Three-to-Two” Hospital Merger Will Reduce Competition
December 16, 2015| Blog| Viewpoint

The General Data Protection Regulation in Bullet Points
December 16, 2015| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
